Gionco David
Chief Accounting Officer at STEMLINE THERAPEUTICS INC; Chief Accounting Officer at SAVIENT PHARMACEUTICALS INC
- Sold, on record
- $1.5M
- Dollars the filings state
- Form 4 sales
- 26
- Latest Apr 1, 2020
- Form 144 notices
- 0
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- STEMLINE THERAPEUTICS INCChief Accounting Officer
- SAVIENT PHARMACEUTICALS INCChief Accounting Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- STEMLINE THERAPEUTICS INC108,561 shares
- SAVIENT PHARMACEUTICALS INC76,192 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale STEMLINE THERAPEUTICS INCPlan not statedFeb 25, 2019 2019
Sold 8,563 shares at $12.03 ($103k)
Gionco David, Chief Accounting Officer
Sold 3.4% of holdings ($3M position)240,341 shares left1.6x usual sizeFiling
- 2 Form 4 sale STEMLINE THERAPEUTICS INCPlan not statedMar 7, 2019 +10 days
Sold 1,381 shares at $11.32 ($16k)
Gionco David, Chief Accounting Officer
Sold 0.6% of holdings ($2.7M position)238,960 shares left0.2x usual sizeFiling
- 3 Form 4 sale STEMLINE THERAPEUTICS INCPlan not statedMar 12, 2019 +5 days
Sold 14,022 shares at $11.11 ($156k)
Gionco David, Chief Accounting Officer
Sold 5.9% of holdings ($2.7M position)224,938 shares left2.2x usual sizeFiling
- 4 Form 4 sale STEMLINE THERAPEUTICS INCPlan not statedDec 27, 2019 +290 days
Sold 4,517 shares at $10.84 ($49k)
Gionco David, Chief Accounting Officer
Sold 1.9% of holdings ($2.6M position)235,421 shares left0.5x usual sizeFiling
- 5 Form 4 sale STEMLINE THERAPEUTICS INCPlan not statedFeb 25, 2020 +60 days
Sold 9,147 shares at $6.43 ($59k)
Gionco David, Chief Accounting Officer
Sold 2.7% of holdings ($2.2M position)333,591 shares left1.1x usual sizeFiling
- 6 Form 4 sale STEMLINE THERAPEUTICS INCPlan not statedMar 10, 2020 +14 days
Sold 13,857 shares at $4.98 ($69k)
Gionco David, Chief Accounting Officer
Sold 4.2% of holdings ($1.7M position)319,734 shares left1.6x usual sizeFiling
- 7 Form 4 sale STEMLINE THERAPEUTICS INCPlan not statedMar 16, 2020 +6 days
Sold 2,849 shares at $3.88 ($11k)
Gionco David, Chief Accounting Officer
Sold 0.9% of holdings ($1.2M position)316,885 shares left0.3x usual sizeFiling
- 8 Form 4 sale STEMLINE THERAPEUTICS INCPlan not statedApr 1, 2020 +16 days
Sold 11,524 shares at $4.79 ($55k)
Gionco David, Chief Accounting Officer
Sold 3.9% of holdings ($1.4M position)282,878 shares left1.3x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (26)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Apr 1, 2020 | Apr 3, 2020 | STEMLINE THERAPEUTICS INC | Chief Accounting Officer | Form 4 sale | 11,524 | $55k | 3.9% | Plan not stated | SEC |
| Mar 16, 2020 | Mar 20, 2020 | STEMLINE THERAPEUTICS INC | Chief Accounting Officer | Form 4 sale | 2,849 | $11k | 0.9% | Plan not stated | SEC |
| Mar 10, 2020 | Mar 13, 2020 | STEMLINE THERAPEUTICS INC | Chief Accounting Officer | Form 4 sale | 13,857 | $69k | 4.2% | Plan not stated | SEC |
| Feb 25, 2020 | Feb 28, 2020 | STEMLINE THERAPEUTICS INC | Chief Accounting Officer | Form 4 sale | 9,147 | $59k | 2.7% | Plan not stated | SEC |
| Dec 27, 2019 | Jan 3, 2020 | STEMLINE THERAPEUTICS INC | Chief Accounting Officer | Form 4 sale | 4,517 | $49k | 1.9% | Plan not stated | SEC |
| Mar 12, 2019 | Mar 15, 2019 | STEMLINE THERAPEUTICS INC | Chief Accounting Officer | Form 4 sale | 14,022 | $156k | 5.9% | Plan not stated | SEC |
| Mar 7, 2019 | Mar 8, 2019 | STEMLINE THERAPEUTICS INC | Chief Accounting Officer | Form 4 sale | 1,381 | $16k | 0.6% | Plan not stated | SEC |
| Feb 25, 2019 | Feb 27, 2019 | STEMLINE THERAPEUTICS INC | Chief Accounting Officer | Form 4 sale | 8,563 | $103k | 3.4% | Plan not stated | SEC |
| Mar 12, 2018 | Mar 14, 2018 | STEMLINE THERAPEUTICS INC | Chief Accounting Officer | Form 4 sale | 9,183 | $160k | 4.8% | Plan not stated | SEC |
| Mar 7, 2018 | Mar 9, 2018 | STEMLINE THERAPEUTICS INC | Chief Accounting Officer | Form 4 sale | 1,413 | $23k | 0.9% | Plan not stated | SEC |
| Feb 27, 2018 | Feb 28, 2018 | STEMLINE THERAPEUTICS INC | Chief Accounting Officer | Form 4 sale | 8,984 | $157k | 5.5% | Plan not stated | SEC |
| Jan 17, 2018 | Jan 19, 2018 | STEMLINE THERAPEUTICS INC | Chief Accounting Officer | Form 4 sale | 4,250 | $57k | 2.5% | Plan not stated | SEC |
| Mar 7, 2017 | Mar 9, 2017 | STEMLINE THERAPEUTICS INC | Chief Accounting Officer | Form 4 sale | 1,116 | $9k | 1.2% | Plan not stated | SEC |
| Feb 28, 2017 | Mar 1, 2017 | STEMLINE THERAPEUTICS INC | Chief Accounting Officer | Form 4 sale | 6,486 | $45k | 6.3% | Plan not stated | SEC |
| Jan 19, 2017 | Jan 24, 2017 | STEMLINE THERAPEUTICS INC | Chief Accounting Officer | Form 4 sale | 3,593 | $41k | 3.4% | Plan not stated | SEC |
| Mar 8, 2016 | Mar 10, 2016 | STEMLINE THERAPEUTICS INC | Chief Accounting Officer | Form 4 sale | 1,148 | $6k | 1.1% | Plan not stated | SEC |
| Jan 20, 2016 | Jan 21, 2016 | STEMLINE THERAPEUTICS INC | Chief Accounting Officer | Form 4 sale | 3,217 | $15k | 8.4% | Plan not stated | SEC |
| Jan 20, 2015 | Jan 21, 2015 | STEMLINE THERAPEUTICS INC | Chief Accounting Officer | Form 4 sale | 3,311 | $47k | 11.0% | Plan not stated | SEC |
| Oct 15, 2013 | Oct 17, 2013 | SAVIENT PHARMACEUTICALS INC | Chief Accounting Officer | Form 4 sale | 47,876 | $4k | 57.2% | Unusual | SEC |
| Mar 6, 2013 | Mar 8, 2013 | SAVIENT PHARMACEUTICALS INC | Group VP & Chief Acct. Officer | Form 4 sale | 1,560 | $1k | 1.8% | Plan not stated | SEC |
| Jan 24, 2011 | Jan 27, 2011 | SAVIENT PHARMACEUTICALS INC | Group VP & CFO | Form 4 sale | 2,032 | $20k | 4.5% | Plan not stated | SEC |
| Dec 20, 2010 | Dec 30, 2010 | SAVIENT PHARMACEUTICALS INC | Group VP & CFO | Form 4 sale | 1,536 | $18k | 3.3% | Plan not stated | SEC |
| Feb 16, 2010 | Feb 17, 2010 | SAVIENT PHARMACEUTICALS INC | Group VP & CFO | Form 4 sale | 1,253 | $17k | 3.9% | Plan not stated | SEC |
| Feb 9, 2010 | Feb 11, 2010 | SAVIENT PHARMACEUTICALS INC | Group VP & CFO | Form 4 sale | 2,037 | $26k | 5.9% | Plan not stated | SEC |
| Dec 21, 2009 | Dec 22, 2009 | SAVIENT PHARMACEUTICALS INC | VP, CFO | Form 4 sale | 1,511 | $20k | 4.2% | Plan not stated | SEC |
| Sep 15, 2009 | Sep 15, 2009 | SAVIENT PHARMACEUTICALS INC | Group VP, CFO | Form 4 sale | 18,387 | $287k | 33.9% | Unusual | SEC |